In-vitro activities of voriconazole, itraconazole and Amphotericin B against Aspergillus species

O. C. Abraham, Elias Kurian Manavathu, P. H. Chandrasekar

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In vitro susceptibility testing for filamentous fungi is under development. Using the broth macrodilution method, we compared the in vitro activities of Voriconazole (VCZ), Itraconazole (ITZ) and Amphotericin B (AB) against 216 clinical isolates of Aspergillus spp. (142 isolates of A. fumigatus and 74 of non-fumigatus Aspergillus spp.). 0.5 ml of PYG medium (1 g peptone, 1 g yeast extract and 3 g dextrose per liter distilled water) with various concentrations of the antifungal drug and 0.5 ml conidial suspension (1 × 104 cfu/ml) was incubated at 37 °C for 48 h and MIC endpoints were read visually. The MIC in micrograms/ml (mean+/-SD, range) for A. fumigatus were as follows: VCZ 0.88+/-0.54,0.25-4; ITZ 0.54+/-0.46,0.25-4; AB 2.16+/-1.64, 0.5-8. MIC90 were as follows: VCZ 2, ITZ 1, AB 4. MICs for non-fumigatus Aspergillus spp. were: VCZ 1.57+/-1.17, 0.25-4; ITZ 1.74+/-1.63,0.25-4; AB 2.88+/-1.47,0.5-8. MIC90 for this group were: VCZ 4, ITZ 4, AB 4.The mean MICs of azoles (VCZ and ITZ) were 2 3 times higher for the non-fumigatus Aspergillus spp. Our study shows that VCZ is as effective as ITZ and AB against Aspergillus (fumigatus and non-fumigatus spp.) in vitro and that non-fumigatus Aspergillus is less susceptible than A. fumigatus to the azole antifungals tested.

Original languageEnglish (US)
Number of pages1
JournalClinical Infectious Diseases
Volume25
Issue number2
StatePublished - Dec 1 1997

Fingerprint

Itraconazole
Amphotericin B
Aspergillus
Azoles
Peptones
Aspergillus fumigatus
In Vitro Techniques
Voriconazole
Suspensions
Fungi
Yeasts
Glucose
Water
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

In-vitro activities of voriconazole, itraconazole and Amphotericin B against Aspergillus species. / Abraham, O. C.; Manavathu, Elias Kurian; Chandrasekar, P. H.

In: Clinical Infectious Diseases, Vol. 25, No. 2, 01.12.1997.

Research output: Contribution to journalArticle

Abraham, O. C. ; Manavathu, Elias Kurian ; Chandrasekar, P. H. / In-vitro activities of voriconazole, itraconazole and Amphotericin B against Aspergillus species. In: Clinical Infectious Diseases. 1997 ; Vol. 25, No. 2.
@article{09724b74991b4de0aa2e1036432ef9e8,
title = "In-vitro activities of voriconazole, itraconazole and Amphotericin B against Aspergillus species",
abstract = "In vitro susceptibility testing for filamentous fungi is under development. Using the broth macrodilution method, we compared the in vitro activities of Voriconazole (VCZ), Itraconazole (ITZ) and Amphotericin B (AB) against 216 clinical isolates of Aspergillus spp. (142 isolates of A. fumigatus and 74 of non-fumigatus Aspergillus spp.). 0.5 ml of PYG medium (1 g peptone, 1 g yeast extract and 3 g dextrose per liter distilled water) with various concentrations of the antifungal drug and 0.5 ml conidial suspension (1 × 104 cfu/ml) was incubated at 37 °C for 48 h and MIC endpoints were read visually. The MIC in micrograms/ml (mean+/-SD, range) for A. fumigatus were as follows: VCZ 0.88+/-0.54,0.25-4; ITZ 0.54+/-0.46,0.25-4; AB 2.16+/-1.64, 0.5-8. MIC90 were as follows: VCZ 2, ITZ 1, AB 4. MICs for non-fumigatus Aspergillus spp. were: VCZ 1.57+/-1.17, 0.25-4; ITZ 1.74+/-1.63,0.25-4; AB 2.88+/-1.47,0.5-8. MIC90 for this group were: VCZ 4, ITZ 4, AB 4.The mean MICs of azoles (VCZ and ITZ) were 2 3 times higher for the non-fumigatus Aspergillus spp. Our study shows that VCZ is as effective as ITZ and AB against Aspergillus (fumigatus and non-fumigatus spp.) in vitro and that non-fumigatus Aspergillus is less susceptible than A. fumigatus to the azole antifungals tested.",
author = "Abraham, {O. C.} and Manavathu, {Elias Kurian} and Chandrasekar, {P. H.}",
year = "1997",
month = "12",
day = "1",
language = "English (US)",
volume = "25",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - In-vitro activities of voriconazole, itraconazole and Amphotericin B against Aspergillus species

AU - Abraham, O. C.

AU - Manavathu, Elias Kurian

AU - Chandrasekar, P. H.

PY - 1997/12/1

Y1 - 1997/12/1

N2 - In vitro susceptibility testing for filamentous fungi is under development. Using the broth macrodilution method, we compared the in vitro activities of Voriconazole (VCZ), Itraconazole (ITZ) and Amphotericin B (AB) against 216 clinical isolates of Aspergillus spp. (142 isolates of A. fumigatus and 74 of non-fumigatus Aspergillus spp.). 0.5 ml of PYG medium (1 g peptone, 1 g yeast extract and 3 g dextrose per liter distilled water) with various concentrations of the antifungal drug and 0.5 ml conidial suspension (1 × 104 cfu/ml) was incubated at 37 °C for 48 h and MIC endpoints were read visually. The MIC in micrograms/ml (mean+/-SD, range) for A. fumigatus were as follows: VCZ 0.88+/-0.54,0.25-4; ITZ 0.54+/-0.46,0.25-4; AB 2.16+/-1.64, 0.5-8. MIC90 were as follows: VCZ 2, ITZ 1, AB 4. MICs for non-fumigatus Aspergillus spp. were: VCZ 1.57+/-1.17, 0.25-4; ITZ 1.74+/-1.63,0.25-4; AB 2.88+/-1.47,0.5-8. MIC90 for this group were: VCZ 4, ITZ 4, AB 4.The mean MICs of azoles (VCZ and ITZ) were 2 3 times higher for the non-fumigatus Aspergillus spp. Our study shows that VCZ is as effective as ITZ and AB against Aspergillus (fumigatus and non-fumigatus spp.) in vitro and that non-fumigatus Aspergillus is less susceptible than A. fumigatus to the azole antifungals tested.

AB - In vitro susceptibility testing for filamentous fungi is under development. Using the broth macrodilution method, we compared the in vitro activities of Voriconazole (VCZ), Itraconazole (ITZ) and Amphotericin B (AB) against 216 clinical isolates of Aspergillus spp. (142 isolates of A. fumigatus and 74 of non-fumigatus Aspergillus spp.). 0.5 ml of PYG medium (1 g peptone, 1 g yeast extract and 3 g dextrose per liter distilled water) with various concentrations of the antifungal drug and 0.5 ml conidial suspension (1 × 104 cfu/ml) was incubated at 37 °C for 48 h and MIC endpoints were read visually. The MIC in micrograms/ml (mean+/-SD, range) for A. fumigatus were as follows: VCZ 0.88+/-0.54,0.25-4; ITZ 0.54+/-0.46,0.25-4; AB 2.16+/-1.64, 0.5-8. MIC90 were as follows: VCZ 2, ITZ 1, AB 4. MICs for non-fumigatus Aspergillus spp. were: VCZ 1.57+/-1.17, 0.25-4; ITZ 1.74+/-1.63,0.25-4; AB 2.88+/-1.47,0.5-8. MIC90 for this group were: VCZ 4, ITZ 4, AB 4.The mean MICs of azoles (VCZ and ITZ) were 2 3 times higher for the non-fumigatus Aspergillus spp. Our study shows that VCZ is as effective as ITZ and AB against Aspergillus (fumigatus and non-fumigatus spp.) in vitro and that non-fumigatus Aspergillus is less susceptible than A. fumigatus to the azole antifungals tested.

UR - http://www.scopus.com/inward/record.url?scp=0344313824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0344313824&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0344313824

VL - 25

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 2

ER -